C4 Therapeutics Inc
NASDAQ:CCCC
C4 Therapeutics Inc
NASDAQ:CCCC
Price:
6.74 USD
4.82%
Market Closed
Updated:
May 5, 2024
C4 Therapeutics Inc
Operating Expenses
|
C4 Therapeutics Inc
Operating Expenses Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
Operating Expenses
-$159.8m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Expenses
-$19.5B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Expenses
-$12.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Expenses
-$11.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Expenses
-$4.8B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Expenses
-$7.1B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-20%
|
See Also
What is C4 Therapeutics Inc's Operating Expenses?
Operating Expenses
-159.8m
USD
-159.8m
USD
Based on the financial report for Dec 31, 2023, C4 Therapeutics Inc's Operating Expenses amounts to -159.8m USD.
What is C4 Therapeutics Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-35%
-35%
Over the last year, the Operating Expenses growth was 1%. The average annual Operating Expenses growth rates for C4 Therapeutics Inc have been -19% over the past three years , -35% over the past five years .
You don't have any saved screeners yet
